KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Long-Term Debt Issuances (2018)

Supernus Pharmaceuticals (SUPN) has disclosed Long-Term Debt Issuances for 2 consecutive years, with $402.5 million as the latest value for Q1 2018.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A to $402.5 million in Q1 2018 year-over-year; TTM through Dec 2018 was $402.5 million, a N/A change, with the full-year FY2018 number at $402.5 million, changed N/A from a year prior.
  • Long-Term Debt Issuances was $402.5 million for Q1 2018 at Supernus Pharmaceuticals, up from $15.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $402.5 million in Q1 2018 to a low of $402.5 million in Q1 2018.